Effects of hCG on DA neuronal death of Parkinson's disease

Parkinson's disease (PD) is the second most common neurodegenerative disease worldwide, with the incidence in men being about twice as compared to women. Gender differences may provide clues for finding key targets that mediate the death of dopaminergic (DA) neurons in PD. Luteinizing hormone (...

Full description

Saved in:
Bibliographic Details
Published in:Biochemical and biophysical research communications 2022-08, Vol.617 (Pt 2), p.41-47
Main Authors: Wang, Shi-min, Wang, Qin, Ye, Li-yan, Chen, Shao-xia, Tao, Liang, Yang, Zhao-shou
Format: Article
Language:English
Subjects:
Dopaminergic neurons
hCG
LHCGR
MPTP
Parkinson's disease
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Parkinson's disease (PD) is the second most common neurodegenerative disease worldwide, with the incidence in men being about twice as compared to women. Gender differences may provide clues for finding key targets that mediate the death of dopaminergic (DA) neurons in PD. Luteinizing hormone (LH), analog of human chorionic gonadotropin (hCG), and their receptor, luteinizing hormone/choriogonadotropin receptor (LHCGR), are associated with the pathogenesis of PD. Movement-related symptoms are partially improved by hCG in PD patients. However, the relationship between hCG and PD, as well as its roles in mediating DA neuronal death, has not been elucidated. In this study, we investigated the potential of hCG as a treatment during PD progression. After establishment of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced PD mouse models, we found that hCG restored the decrease of LHCGR activity caused by down-regulation of LH in the substantia nigra. Furthermore, the reduction of LHCGR activity led to DA neuronal death through knocking down the LHCGR in DA neurons by AAV-mTH-shRNA. Treatment with hCG alleviated the DA neuronal death induced by MPTP. Finally, hCG exerted neuroprotective effects by inhibiting the activation of glycogen synthase kinase 3 beta (GSK3β) in our MPTP-induced PD mouse and MPP+-treated SH-SY5Y cell models. Together, these results demonstrate that hCG exerts neuroprotective effects for PD through LHCGR, and the inhibition of GSK3β activation is involved in this protective effect, suggesting that hCG can be taken as a potential therapeutic for the treatment of PD. •hCG ameliorates the activity of LH/CG receptor (LHCGR) after MPTP intoxication.•Knockdown of LHCGR aggravates MPTP-induced nigral dopaminergic neurodegeneration.•hCG exerts neuroprotective effects by inhibiting the activity of GSK3β.
ISSN:0006-291X
1090-2104
DOI:10.1016/j.bbrc.2022.05.089